{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:13:55Z","timestamp":1765444435620,"version":"3.41.0"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004602","name":"Program for New Century Excellent Talents in University","doi-asserted-by":"publisher","award":["NCET-13-0605"],"award-info":[{"award-number":["NCET-13-0605"]}],"id":[{"id":"10.13039\/501100004602","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The New Xiangya Talent Project of the Third Xiangya Hospital of Central South University","award":["20150218"],"award-info":[{"award-number":["20150218"]}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["14JJ7001"],"award-info":[{"award-number":["14JJ7001"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81102512"],"award-info":[{"award-number":["81102512"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1111\/jcpt.12394","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T04:32:43Z","timestamp":1462509163000},"page":"341-347","source":"Crossref","is-referenced-by-count":7,"title":["Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients"],"prefix":"10.1155","volume":"41","author":[{"given":"L.-Y.","family":"Zhou","sequence":"first","affiliation":[{"name":"Clinical Pharmacy and Pharmacology Research Institute; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.-C.","family":"Zuo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology Research Institute; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Transplantation; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology Research Institute; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.-J.","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology Research Institute; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.-N.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology Research Institute; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Yuan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology Research Institute; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Transplantation; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.-J.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Transplantation; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.-X.","family":"Peng","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology Research Institute; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.-Z.","family":"Ming","sequence":"additional","affiliation":[{"name":"Department of Transplantation; Third Xiangya Hospital; Central South University; Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"key":"10.1111\/jcpt.12394-BIB0001|jcpt12394-cit-0001","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00467-007-0627-7","article-title":"Hypertension after renal transplantation","volume":"24","author":"Seeman","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/jcpt.12394-BIB0002|jcpt12394-cit-0002","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1674-8301(10)60044-9","article-title":"The effects of diltiazem in renal transplantation patients treated with cyclosporine","volume":"24","author":"Xue","year":"2010","journal-title":"J Biomed Res"},{"key":"10.1111\/jcpt.12394-BIB0003|jcpt12394-cit-0003","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.ajkd.2010.10.048","article-title":"Hypertension after kidney transplant","volume":"57","author":"Mangray","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12394-BIB0004|jcpt12394-cit-0004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2125.1996.34412.x","article-title":"Diltiazem increases blood concentration of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients","volume":"4","author":"Bleck","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12394-BIB0005|jcpt12394-cit-0005","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0041-1345(98)00381-9","article-title":"Study of neoral kinetics in adult renal transplantation treated with diltiazem","volume":"30","author":"Mezzano","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1111\/jcpt.12394-BIB0006|jcpt12394-cit-0006","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s002280050644","article-title":"Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients","volume":"55","author":"Asberg","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12394-BIB0007|jcpt12394-cit-0007","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharma Ther"},{"key":"10.1111\/jcpt.12394-BIB0008|jcpt12394-cit-0008","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/tpj.2010.42","article-title":"Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective","volume":"11","author":"Li","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1111\/jcpt.12394-BIB0009|jcpt12394-cit-0009","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00228-008-0577-4","article-title":"Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem","volume":"65","author":"Wang","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12394-BIB0010|jcpt12394-cit-0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1067\/mcp.2002.127396","article-title":"Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype","volume":"72","author":"Molden","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12394-BIB0011|jcpt12394-cit-0011","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1248\/bpb1978.9.547","article-title":"Hypotensive response of spontaneously hypertensive rats to centrally administered diltiazem and its metabolites: in relevance to the hypotensive action by oral administration","volume":"9","author":"Narita","year":"1986","journal-title":"J Pharmacobiodyn"},{"key":"10.1111\/jcpt.12394-BIB0012|jcpt12394-cit-0012","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.2042-7158.1998.tb03341.x","article-title":"Pharmacokinetics and hypotensive effect of diltiazem in rabbits: comparison of diltiazem with its major metabolites","volume":"50","author":"Yeung","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"10.1111\/jcpt.12394-BIB0013|jcpt12394-cit-0013","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0022-3565(24)36788-6","article-title":"Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites","volume":"282","author":"Sutton","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jcpt.12394-BIB0014|jcpt12394-cit-0014","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","article-title":"Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method","volume":"10","author":"Ozdemir","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1111\/jcpt.12394-BIB0015|jcpt12394-cit-0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cccn.2004.11.005","article-title":"CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population","volume":"353","author":"Hu","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1111\/jcpt.12394-BIB0016|jcpt12394-cit-0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clpt.2004.03.009","article-title":"Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states","volume":"76","author":"Yu","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12394-BIB0017|jcpt12394-cit-0017","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00228-008-0520-8","article-title":"Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients","volume":"64","author":"Qiu","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12394-BIB0018|jcpt12394-cit-0018","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12024-010-9188-3","article-title":"Review: pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects","volume":"7","author":"Pilgrim","year":"2011","journal-title":"Forensic Sci Med Pathol"},{"key":"10.1111\/jcpt.12394-BIB0019|jcpt12394-cit-0019","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jcpt.12394-BIB0020|jcpt12394-cit-0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":"Common allelic variants of cytochrome P4503A4 and their prevalence in different populations","volume":"12","author":"Lamba","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"suppl 2","key":"10.1111\/jcpt.12394-BIB0021|jcpt12394-cit-0021","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.taap.2005.01.030","article-title":"The human genome project and novel aspects of cytochrome P450 research","volume":"207","author":"Ingelman-Sundberg","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1111\/jcpt.12394-BIB0022|jcpt12394-cit-0022","first-page":"29","article-title":"Individualized drug therapy","volume":"10","author":"Daly","year":"2007","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10.1111\/jcpt.12394-BIB0023|jcpt12394-cit-0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2000.104391","article-title":"CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity","volume":"67","author":"Sata","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12394-BIB0024|jcpt12394-cit-0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2350-6-19","article-title":"CYP3A4 and CYP3A5 genotyping by Pyrosequencing","volume":"6","author":"Garsa","year":"2005","journal-title":"BMC Med Genet"},{"key":"10.1111\/jcpt.12394-BIB0025|jcpt12394-cit-0025","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1086\/426406","article-title":"CYP3A variation and the evolution of saltsensitivity variants","volume":"75","author":"Thompson","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1111\/jcpt.12394-BIB0026|jcpt12394-cit-0026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2350-11-111","article-title":"Research article genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?","volume":"11","author":"Kudzi","year":"2010","journal-title":"BMC Med Gen"},{"key":"10.1111\/jcpt.12394-BIB0027|jcpt12394-cit-0027","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/00498250601149206","article-title":"Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects","volume":"37","author":"Hu","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1111\/jcpt.12394-BIB0028|jcpt12394-cit-0028","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/humu.9210","article-title":"Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japane se population","volume":"23","author":"Fukushima- Uesaka","year":"2004","journal-title":"Hum Mutat"},{"key":"10.1111\/jcpt.12394-BIB0029|jcpt12394-cit-0029","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans","volume":"70","author":"Kim","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12394-BIB0030|jcpt12394-cit-0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00228-009-0726-4","article-title":"CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients","volume":"66","author":"Zhang","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12394-BIB0031|jcpt12394-cit-0031","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2217\/pgs.11.33","article-title":"Impact of the CYP3A4*1Gpolymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients","volume":"12","author":"Miura","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12394-BIB0032|jcpt12394-cit-0032","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jcph.229","article-title":"The Effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease","volume":"54","author":"He","year":"2013","journal-title":"J Clin Pharma"},{"key":"10.1111\/jcpt.12394-BIB0033|jcpt12394-cit-0033","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cccn.2005.06.013","article-title":"Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem","volume":"362","author":"Yamamoto","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1111\/jcpt.12394-BIB0034|jcpt12394-cit-0034","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.62.1.162","article-title":"Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism","volume":"62","author":"Lin","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1111\/jcpt.12394-BIB0035|jcpt12394-cit-0035","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.transproceed.2008.04.010","article-title":"Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in asian renal transplant recipients","volume":"40","author":"Loh","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1111\/jcpt.12394-BIB0036|jcpt12394-cit-0036","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1111\/jcpt.12394-BIB0037|jcpt12394-cit-0037","first-page":"257","article-title":"Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects","volume":"68","author":"Zheng","year":"2013","journal-title":"Pharmazie"},{"key":"10.1111\/jcpt.12394-BIB0038|jcpt12394-cit-0038","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0022-3565(24)36788-6","article-title":"Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites","volume":"282","author":"Dylan","year":"1997","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12394","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12394\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T01:05:41Z","timestamp":1748912741000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12394","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"type":"print","value":"0269-4727"}],"subject":[],"published":{"date-parts":[[2016,5,5]]}}}